Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
about
Emerging roles for the non-canonical IKKs in cancerNF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivationA stromal gene signature associated with inflammatory breast cancer.KBERG: KnowledgeBase for Estrogen Responsive Genes.NF-kappa B genes have a major role in inflammatory breast cancerFISim: a new similarity measure between transcription factor binding sites based on the fuzzy integralInflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategiesChallenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast CancerHigh-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endotheliumCore module biomarker identification with network exploration for breast cancer metastasis.Human cytomegalovirus infection enhances NF-κB/p65 signaling in inflammatory breast cancer patients.Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression.A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples.A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers.Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians.NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast CancerDistinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.Genomic and expression analysis of microdissected inflammatory breast cancer.The interaction between ER and NFκB in resistance to endocrine therapy.Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse.Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinomaA new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB familyRelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1.Nitrative and oxidative stress in toxicology and disease.Luteolin protects mice from severe acute pancreatitis by exerting HO-1-mediated anti-inflammatory and antioxidant effectsSyndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysComparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.Role of nuclear factor-ĸB in breast and colorectal cancer.Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced diseaseInflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth.Computational simulations to predict creatine kinase-associated factors: protein-protein interaction studies of brain and muscle types of creatine kinases.
P2860
Q24305225-4D466CF8-232E-4043-B5D9-7D1DB20985CBQ24653076-24920CB9-EEED-466A-A6CB-91BFB8C9693CQ30838525-70C9C6C3-7D88-47BF-801C-D465EF4E0746Q33262961-355AE426-C8CD-40A3-9920-C6173184696CQ33318125-9C0BEE8F-1CB1-4D60-8843-E4E697AB3348Q33483738-21883E4F-DE8F-47B2-BEEC-4D88459DA4CCQ33688446-65B641E0-58E1-4D73-92DD-0A7B22933129Q33760216-E21F472E-57C7-4622-A7F4-7B84633F7FE0Q33826097-59AB7B61-BB60-4A6B-B606-574857A3E6DEQ33870504-65788318-29B7-4225-9810-2C5EE451AEE5Q34078957-F465BDCC-FDB7-4256-9422-E72A71C5685AQ34132404-62A5E2E8-92FC-4FDA-8A2D-D7875952E8AFQ34589568-4915DCFD-880C-40CD-818C-415204CD70F6Q34637826-1BCD1B18-D49B-4982-A7DD-C0E8A93E3948Q35102469-A0712A02-986F-4C88-8C2B-F9B8E358D2EEQ35106947-5B910C4F-2919-4ED9-B18B-A7A186DDB62BQ35150412-E9A8015A-EA79-4F57-84FA-DAD5124458F0Q35156259-4E01A419-F046-4D9F-9643-247E3985A39AQ35469769-0AF11979-0807-4176-8181-BBAD3F18277BQ35496324-E00E3DBE-DA9C-48EB-914F-AC44FF48A513Q35825566-270C6287-5738-4C3E-87FC-03DFE3EA9391Q35985276-E91C8DB3-4BBF-4A97-B1EA-7088E8E5E79EQ36169303-97411FC7-CC16-49B2-8908-D395A4BA3833Q36611440-695C9316-DC4F-46B4-A1CA-473BFA89DE3FQ36672230-0E36533F-FA50-4A64-8AEE-ABE953684131Q36916724-3A65A0A5-7BF2-426F-8748-4ADC265570C8Q36924406-0E1DC143-9549-4F25-8FF6-F41D58151D36Q36958447-143B4237-1941-43DB-B406-2696C7CACAE7Q37151107-B1F43C3F-D3C0-4443-A0EB-415049A9A50BQ37207403-D97516CC-E1E6-4CF6-AB70-2E41C5602A89Q37247886-BBBEBE13-822C-44E7-8FA2-89B113EEA71FQ37402818-ABEF742C-BDD5-45F7-A8AF-167D276055A5Q37527788-A4D98861-90F9-453D-AF55-D047FE20BB08Q37686006-0E066117-DEA4-4276-83EF-35CF30D159D2Q37690619-4115683C-0E47-423D-8DFC-B56F7B4BC73EQ38041500-878BFFB9-A22D-4230-A026-3D865027407CQ38706762-0A82F334-CC3B-4155-B9C5-7E9A749821B3Q41136265-4C6D8821-96E8-4F48-975A-FFA2C56639A0Q42554555-A97DE411-E8A2-4DEF-A7AE-B87A3E7A780AQ42855133-8561752B-956F-4556-A1F3-585C64C28962
P2860
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@ast
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@en
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@nl
type
label
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@ast
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@en
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@nl
prefLabel
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@ast
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@en
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@nl
P2093
P1476
Nuclear factor-kappaB signatur ...... ear factor-kappaB DNA-binding.
@en
P2093
Eric A Van Marck
Gert G Van den Eynden
Hilde J Elst
Ilse Van der Auwera
Joost Weyler
Luc Y Dirix
Peter B Vermeulen
Peter van Dam
Steven J Van Laere
P304
P356
10.1158/1078-0432.CCR-05-2800
P407
P433
P577
2006-06-01T00:00:00Z